SG11201501292UA - Anxiolytic composition, formulation and method of use - Google Patents

Anxiolytic composition, formulation and method of use

Info

Publication number
SG11201501292UA
SG11201501292UA SG11201501292UA SG11201501292UA SG11201501292UA SG 11201501292U A SG11201501292U A SG 11201501292UA SG 11201501292U A SG11201501292U A SG 11201501292UA SG 11201501292U A SG11201501292U A SG 11201501292UA SG 11201501292U A SG11201501292U A SG 11201501292UA
Authority
SG
Singapore
Prior art keywords
formulation
anxiolytic composition
anxiolytic
composition
Prior art date
Application number
SG11201501292UA
Other languages
English (en)
Inventor
Stuart L Weg
Original Assignee
Stuart L Weg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stuart L Weg filed Critical Stuart L Weg
Publication of SG11201501292UA publication Critical patent/SG11201501292UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201501292UA 2012-08-23 2013-08-23 Anxiolytic composition, formulation and method of use SG11201501292UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261692380P 2012-08-23 2012-08-23
PCT/US2013/056424 WO2014031975A1 (en) 2012-08-23 2013-08-23 Anxiolytic composition, formulation and method of use

Publications (1)

Publication Number Publication Date
SG11201501292UA true SG11201501292UA (en) 2015-05-28

Family

ID=50148531

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201501292UA SG11201501292UA (en) 2012-08-23 2013-08-23 Anxiolytic composition, formulation and method of use

Country Status (11)

Country Link
US (3) US20140057988A1 (ru)
EP (2) EP3878442A1 (ru)
JP (2) JP6722453B2 (ru)
KR (1) KR20150096370A (ru)
CN (1) CN104902883A (ru)
AU (1) AU2013305580A1 (ru)
BR (1) BR112015003796A2 (ru)
IL (1) IL237340A0 (ru)
MX (1) MX2015002378A (ru)
SG (1) SG11201501292UA (ru)
WO (1) WO2014031975A1 (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014152196A1 (en) 2013-03-15 2014-09-25 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
CN105073103A (zh) * 2013-03-15 2015-11-18 詹森药业有限公司 S-盐酸氯胺酮的药物组合物
KR102424765B1 (ko) 2013-04-12 2022-07-22 이칸 스쿨 오브 메디슨 엣 마운트 시나이 외상후 스트레스 장애의 치료 방법
RS62516B1 (sr) 2013-09-13 2021-11-30 Univ Chiba Nat Univ Corp Primena r-ketamina i njegove soli kao farmaceutskih proizvoda
US10098854B2 (en) 2014-08-13 2018-10-16 Janssen Pharmaceutica Nv Method for the treatment of depression
JP6757537B2 (ja) * 2014-08-29 2020-09-23 公益財団法人ヒューマンサイエンス振興財団 神経疾患モデル動物の製造方法及び神経疾患モデル動物
CN107208133A (zh) 2014-09-15 2017-09-26 詹森药业有限公司 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法
EP3085366A1 (en) * 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
KR20240068766A (ko) * 2015-05-22 2024-05-17 비스타젠 쎄라퓨틱스, 인크. L-４-클로로키누레닌의 치료적 용도
JP6845162B2 (ja) 2015-06-27 2021-03-17 シェノックス・ファーマシューティカルズ・エルエルシー ケタミン経皮送達システム
CN105249531A (zh) * 2015-08-06 2016-01-20 云南中烟工业有限责任公司 一种金丝楠木提取物的制备方法及其应用
ES2876898T3 (es) * 2015-09-08 2021-11-15 Childrens Hospital Philadelphia Diagnóstico y tratamiento del trastorno de ansiedad
US11110070B2 (en) * 2015-11-17 2021-09-07 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
SG11202005896WA (en) 2017-12-22 2020-07-29 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
CN118453559A (zh) 2018-02-15 2024-08-09 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
US11426367B2 (en) 2018-05-04 2022-08-30 Perception Neuroscience, Inc. Methods of treating substance abuse
KR20210125984A (ko) 2019-02-22 2021-10-19 하리마카세이 가부시기가이샤 고형 땜납재의 도포 방법, 도포물의 제조 방법, 도포 장치, 및 롤 형상의 고형 땜납재
MX2021010683A (es) 2019-03-05 2021-12-10 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
WO2020232246A1 (en) * 2019-05-15 2020-11-19 The Trustees Of Columbia University In The City Of New York Compositions and methods against stress-induced affective disorders and their associated symptoms
WO2020240279A1 (en) * 2019-05-31 2020-12-03 Lionheart Pharmaceuticals Aps Intranasal administration of ketamine to cluster headache patients

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US5679714A (en) * 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
US8785500B2 (en) * 2006-03-22 2014-07-22 Icahn School Of Medicine At Mount Sinai Intranasal administration of ketamine to treat depression
US7638651B2 (en) * 2007-04-26 2009-12-29 Auspex Pharmaceuticals Substituted cyclohexanones
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder

Also Published As

Publication number Publication date
BR112015003796A2 (pt) 2017-07-04
CN104902883A (zh) 2015-09-09
US20220160655A1 (en) 2022-05-26
JP2018162302A (ja) 2018-10-18
JP2016501828A (ja) 2016-01-21
KR20150096370A (ko) 2015-08-24
JP6771512B2 (ja) 2020-10-21
EP2887930A4 (en) 2016-03-23
IL237340A0 (en) 2015-04-30
EP2887930A1 (en) 2015-07-01
EP3878442A1 (en) 2021-09-15
WO2014031975A1 (en) 2014-02-27
MX2015002378A (es) 2015-09-25
US20180235906A1 (en) 2018-08-23
AU2013305580A1 (en) 2015-04-09
JP6722453B2 (ja) 2020-07-15
US20140057988A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
IL237340A0 (en) An anti-anxiety preparation, its formulation and method of using it
HRP20181628T1 (hr) Spojevi i postupci za njihovu upotrebu
AP3965A (en) Anthelminitic compounds and compositions and method of using thereof
EP2834322A4 (en) BIOCHARBON COMPOSITIONS AND METHODS OF USE
HK1206264A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
HK1198365A1 (en) Imidazopyridine compounds, compositions and methods of use
EP2906041A4 (en) COMPOSITIONS AND METHODS OF USING INAPPETENCE COMPOUND
EP2807256A4 (en) MYONECTIN (CTRP15), COMPOSITION COMPRISING SAME AND METHODS OF USE
EP2852370A4 (en) FLASH-CONTAINING COMPOSITIONS AND METHODS OF USE
EP2844219A4 (en) SENSITIZING COMPOSITION AND METHOD OF USE
EP2800568A4 (en) COMPOSITIONS, USE METHOD AND TREATMENT METHOD THEREFOR
HK1216891A1 (zh) 苔蘚素組合物、其製備方法和用途
EP2809337A4 (en) EFFECTORS OF SS-ARRESTINE AND COMPOSITIONS AND METHODS OF USE THEREOF
GB201222820D0 (en) Woolscouring method and composition
ZA201409028B (en) Cosmetic composition and method for using thereof
EP2859071A4 (en) CHEMICAL COMPOSITIONS AND METHODS OF USE
GB201206859D0 (en) Method and composition
IL238934A0 (en) Methods for the preparation of phenyloxymethyl-nitro-imidazole derivatives and their use
ZA201500172B (en) Plant-disease-control composition and plant-disease-control method
EP2839023A4 (en) EASY TO USE PRIMER AND USE METHOD THEREFOR
AU2012901658A0 (en) Compositions and methods of use
EP2841164A4 (en) COMPOSITIONS AND USE PROCEDURES FOR THE SKIN
AU2012900650A0 (en) Compounds and methods of their use
AU2012900651A0 (en) Compounds and methods of their use
AU2012905317A0 (en) Methods and Preparation and Use of Xanthorrhoeaceae Compositions